These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30640698)

  • 1. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
    Tripodi E; Cormio G; De Giorgi U; Valabrega G; Rubino D; Lepori S; Maltese G; Sabatucci I; Lorusso D
    Int J Gynecol Cancer; 2019 Jan; 29(1):153-157. PubMed ID: 30640698
    [No Abstract]   [Full Text] [Related]  

  • 2. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
    Tanguay JS; Ansari J; Buckley L; Fernando I
    Int J Gynecol Cancer; 2009 Apr; 19(3):361-6. PubMed ID: 19407560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
    BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
    Collins Y; Lele S
    J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.
    Rabinovich A; Ramanakumar AV; Lau S; Gotlieb WH
    Acta Obstet Gynecol Scand; 2015 Jul; 94(7):776-780. PubMed ID: 25923364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
    Inaba K; Arimoto T; Hoya M; Kawana K; Nakagawa S; Kozuma S; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1255-7. PubMed ID: 21390517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin consolidation therapy.
    Hamm W
    Oncologist; 2006; 11(7):855; author reply 855-6. PubMed ID: 16880247
    [No Abstract]   [Full Text] [Related]  

  • 15. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Pendlebury A; DeBernardo R; Rose PG
    Anticancer Drugs; 2017 Aug; 28(7):815-817. PubMed ID: 28542037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer].
    Lehoczky O; Pulay T
    Magy Onkol; 2006; 50(3):261-4. PubMed ID: 17099788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.